Advocating AI - driven Digital Pathology

aetherAI’s mission is to use state-of-the-art information technology to improve standards of healthcare and quality of human life.

Milestones

aetherSlide adopted by RWTH Aachen University Hospital (Germany).

2025

aetherSlide adopted by major medical centers across Taiwan, including TMU Hospital, Wanfang Hospital, Shuang-Ho Hospital, and Tzu Chi hospitals in Hualien and Dalin.

Filed the listing application for the Taiwan Innovation Board on November 21, 2025.

Core GigaPixel AI large-image computation technology received two U.S. patents.

aetherSlide entered the Japanese market, adopted by National Cancer Center Hospital East, Cancer Institute Hospital (JFCR), and Toyama Prefectural Central Hospital.

2024

aetherSlide adopted by University Hospital Frankfurt (Germany).

aetherSlide adopted by NTU Cancer Center and Tung’s Taichung MetroHarbor Hospital.

Raised NT$765 million in Series B funding, led by CDIB Capital, Quanta Computer, Taiwan Business Bank VC, and Cathay Venture.

Officially listed on Taiwan’s Emerging Stock Board on November 26, 2024.

Achieved ISO/IEC 27001 certification.

Awarded the adi15 Digital Innovation Award by the Ministry of Digital Affairs.

2023

Selected for the inaugural Taiwan AI Awards.

aetherSlide adopted by Changhua Christian Hospital, Cathay General Hospital, and Tri-Service General Hospital.

Annual revenue surpassed NT$100 million, with over 40% from overseas.

Raised over NT$200 million in Series A+ funding from Taiwan Business Bank VC, Ono Digital Health Investment (Japan), Cathay General Hospital, and Quanta Computer.

2022

aetherAI Hema received multiple major awards:
• Taipei BioTech Award – Cross-Disciplinary Excellence Gold Award
• National Biotechnology & Medical Care Quality Award – Medical Device Gold Medal
• Taiwan Excellence Award

aetherAI Endo became the first domestically developed AI colon polyp detection system to receive TFDA medical device approval.

aetherSlide adopted by Chung Shan Medical University Hospital.

aetherSlide entered the European market, adopted by Tübingen University Hospital.

Commissioned by Ono Pharmaceutical (Japan) for AI-assisted multiplex immunofluorescence image analysis.

aetherSlide adopted by Taipei Veterans General Hospital and Mackay Memorial Hospital.

2021

Released the AI-assisted colon polyp detection system aetherAI Endo.

Published research on the internally developed GigaPixel AI large-image computation technology in Nature Communications.

Collaborated with Novartis Taiwan and Linkou Chang Gung Memorial Hospital on AI-assisted interpretation for myeloproliferative neoplasms.

aetherSlide adopted by National Taiwan University Hospital.

2020

Awarded the Taipei City Government Spotlight Enterprise Jury Award and R&D Excellence Award.

Raised NT$180 million in Series A funding from Quanta Computer.

Launched aetherAI Hema, the first AI-assisted bone marrow smear classification system.

aetherSlide obtained medical device clearance from the Taiwan FDA.

Received the MOEA Startup Award – Gold Award (Technology Industry Category).

2019

Secured NT$34 million in seed investment from Cathay Venture.

The aetherSlide Digital Pathology Image Management System was adopted by Chang Gung Memorial Hospital (Linkou, Kaohsiung, Keelung, and Chiayi branches).

2018

Began AI pathology collaboration with Linkou Chang Gung Memorial Hospital.

Awarded the NVIDIA GTC Inception Award – Champion.

Received the Meet Neo Star – Jury Grand Prize.

2017

Joined the Ministry of Science and Technology’s big data program for medical imaging.

Presented prototype pathology and AI platforms at Inaugural Taiwan Healthcare+ Expo.

2016

Completed the company’s first commissioned project: a whole-slide fluorescence image–based circulating tumor cell (CTC) computer-aided detection system.

OCT

2015

AetherAI was founded on October 7, 2015

Meet the Team

Joe Yeh

M.D., Co-founder & CEO.

Dr. Joe Yeh holds an M.D. from National Taiwan University and pursued doctoral studies in pathology at the University of Southern California, where he developed a strong interest in computer programming and image analysis. Motivated by the transformative potential of AI in healthcare, he co-founded aetherAI alongside KJB and Steven Yeh.

Dr. Yeh has taught deep learning in medical imaging at National Taiwan University and National Cheng Kung University, and has co-authored several research papers published in prestigious international publications such as Nature Communications.

Steve Yeh

Co-founder and COO

KJB, M.S.

Co-founder and CTO

Core Business

Asia’s leading medical image AI solution provider, aetherAI is dedicated to providing cutting-edge solutions for digital pathology transformation, AI-powered diagnostic support systems, and biopharma enterprise services.

By leveraging state-of-the-art technologies, aetherAI aims to ease the burden on healthcare professionals and improve diagnostic imaging quality. At the forefront of digital pathology AI, aetherAI partners with top medical centers in the US, Taiwan, Japan, and Europe, including UPMC, National Taiwan University Hospital, Kanazawa University, University Hospital Tübingen, etc. aetherAI is also a trusted collaborator for such BioPharma companies as Novartis Taiwan and ACT Genomics, and many more are working with us to accelerate AI applications for research efficiency.